ログイン
お問い合わせ
（旧版）前立腺癌診療ガイドライン 2006年版
書誌情報
第3章 治療総論
参考文献
3 外科治療 ＊この項の文献番号は、「第4章外科治療」の文献番号と対応しています。
| 1） | 中山健夫: EBM を用いた診療ガイドライン作成・活用ガイド．金原出版; 2004． |
| 4） | D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95（18）:1376-83. |
| 5） | Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy:oncological outcome during a 20-year period. J Urol 1999;161（1）:163-8. |
| 6） | D'Amico AV:Predicting prostate-specific antigen recurrence established:now, who will survive? J Clin Oncol. 2002;20（15）:3188-90. |
| 7） | Schild SE, Wong WW, Novicki DE, et al. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Urology. 1996;47（6）:878-81. |
| 8） | Oefelein MG, Smith N, Carter M, et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol. 1995;154（6）:2128-31. |
| 9） | Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281（17）:1591-7. |
| 10） | Scher HI. Management of prostate cancer after prostatectomy:treating the patient, not the PSA. JAMA. 1999 5;281（17）:1642-5. |
| 11） | Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349（9056）:906-10. |
| 12） | Graversen PH, Nielsen KT, Gasser TC, et al. Radical prostatectomy versus expectant primary treatment in stagesI and II prostatic cancer. A fifteen-year follow-up. Urology. 1990;36（6）:493-8. |
| 13） | Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management:a retrospective analysis. Cancer. 2001:91（12）:2302-14. |
| 14） | Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347（11）:781-9. |
| 15） | Elgamal AA, Van Poppel HP, Van de Voorde WM, et al. Impalpable invisible stage T1c prostate cancer:characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol. 1997;157（1）:244-50. |
| 16） | Oesterling JE, Suman VJ, Zincke H, et al. PSA-detected（clinical stage T1c or B0）prostate cancer. Pathologically significant tumors. Urol Clin North Am. 1993;20（4）:687-93. |
| 17） | Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer:the Johns Hopkins experience with tumors found on transurethral resection（stages T1A and T1B）and on needle biopsy（stage T1C）. J Urol. 1994;152:1721-9. |
| 18） | Gibbons RP. Total prostatectomy for clinically localized prostate cancer:long-term surgical results and current morbidity. NCI Monogr. 1988;（7）:123-6. |
| 19） | Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24（2）:395-406. |
| 20） | Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837-42. |
| 21） | Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994;152:1821-5. |
| 22） | Zincke H, Oesterling JE, Blute ML, et al. Long-term（15 years）results after radical prostatectomy for clinically localized（stage T2c or lower）prostate cancer. J Urol. 1994;152:1850-7. |
| 23） | Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28（3）:555-65. |
| 24） | Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34. |
| 25） | Lau WK, Bergstralh EJ, Blute ML, et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer:influence of concomitant pathological variables. J Urol. 2002;167（1）:117-22. |
| 26） | van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer（T3）treated with radical prostatectomy as monotherapy. J Urol 1998;160（4）:1392-7. |
| 27） | Alibhai SM, Naglie G, Nam R, et al. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 2003;21（17）:3318-27. |
| 28） | Coen JJ, Zietman AL, Shipley WU. Prostatectomy or watchful waiting in prostate cancer. N Engl J Med. 2003;348（2）:170-1;author reply. |
| 29） | Grimm MO, Kamphausen S, Hugenschmidt H, et al. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol. 2002;41（6）:628-34;discussion 634. |
| 30） | Lu-Yao GL, McLerran D, Wasson J, et al. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993;269（20）:2633-6. |
| 31） | Eastham JA, Kattan MW, Riedel E, et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. 2003;170:2292-5. |
| 32） | Van Poppel H, Collette L, Kirkali Z, et al. Quality control of radical prostatectomy:a feasibility study. Eur J Cancer. 2001;37（7）:884-91. |
| 33） | Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer:5-year results. J Urol. 2002;167（1）:112-6. |
| 34） | Aus G, Abrahamsson PA, Ahlgren G, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy:a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90:561-6. |
| 35） | Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170（3）:791-4. |
| 37） | Salomon L, Anastasiadis AG, Levrel O, et al. Location of positive surgical margins after retropubic, perineal, and laparoscopic radical prostatectomy for organ-confined prostate cancer. Urology. 2003;61（2）:386-90. |
| 38） | Artibani W, Grosso G, Novara G, et al. Is laparoscopic radical prostatectomy better than traditional retropubic radical prostatectomy? An analysis of peri-operative morbidity in two contemporary series in Italy. Eur Urol. 2003;44（4）:401-6. |
| 39） | Lance RS, Freidrichs PA, Kane C, et al. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group . BJU Int. 2001;87（1）:61-5. |
| 40） | Lodding P, Bergdahl C, Nyberg M, et al. Inguinal hernia after radical retropubic prostatectomy for prostate cancer:a study of incidence and risk factors in comparison to no operation and lymphadenectomy. J Urol. 2001;166（3）:964-7. |
| 41） | Lu-Yao GL, Albertsen P, Warren J, et al. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy - a population-based study. Urology. 1999;54（2）:301-7. |
| 42） | Bishoff JT, Motley G, Optenberg SA, et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol. 1998;160（2）:454-8. |
| 43） | Abbou CC, Salomon L, Hoznek A, et al. Laparoscopic radical prostatectomy:preliminary results. Urology. 2000;55（5）:630-4. |
| 44） | Guillonneau B, el-Fettouh H, Baumert H, et al. Laparoscopic radical prostatectomy:oncological evaluation after 1,000 cases a Montsouris Institute. J Urol. 2003;169（4）:1261-6. |
| 45） | Rassweiler J, Sentker L, Seemann O, et al. Laparoscopic radical prostatectomy with the Heilbronn technique:an analysis of the first 180 cases. J Urol. 2001;166（6）:2101-8. |
| 46） | Arai Y, Egawa S, Terachi T, et al. Morbidity of laparoscopic radical prostatectomy:summary of early multi-institutional experience in Japan. Int J Urol 2003;10（8）:430-4. |
| 47） | Marcovich R, Wojno KJ, Wei JT, et al. Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. Urology. 2000;55（6）:904-8. |
| 48） | Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer：the Prostate Cancer Outcomes Study. JAMA. 2000;283（3）:354-60. |
| 49） | Sokoloff MH, Brendler CB:Indications and contraindications for nerve-sparing radical prostatectomy. Urol Clin North Am. 2001;28（3）:535-43. |
| 50） | Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54（4）:1063-8. |
| 51） | Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-4. |
| 52） | Clark T, Parekh DJ, Cookson MS, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003;169（1）:145-7;discussion 147-8. |
| 53） | Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy:high incidence of lymph node metastasis. J Urol. 2002;167（4）:1681-6. |
| 54） | Freedland SJ, Sutter ME, Dorey F, et al. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61（2）:365-9. |
| 55） | Leibman BD, Dillioglugil O, Wheeler TM, et al. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer. 1995;76（12）:2530-4. |
| 56） | Lattouf JB, Saad F. Digital rectal exam following prostatectomy:is it still necessary with the use of PSA?. Eur Urol. 2003;43（4）:333-6. |
| 57） | Niwakawa M, Tobisu K, Fujimoto H, et al. Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy. Int J Urol. 2002;9（3）:134-40. |
| 62） | Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341（24）:1781-8. |
| 63） | Pisansky TM, Kozelsky TF, Myers RP, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000;163（3）:845-50. |
| 64） | Duchesne GM, Dowling C, Frydenberg M, et al. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy:an Australian multicenter study. Urology. 2003;61（1）:179-83. |
| 65） | Song DY, Thompson TL, Ramakrishnan V, et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology. 2002;60（2）:281-7. |
| 66） | Macdonald OK, Schild SE, Vora SA, et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol. 2003;170（5）:1833-7. |
| 67） | Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21（3）:483-9. |
| 68） | Catton C, Gospodarowicz M, Warde P, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001;59（1）:51-60. |
| 69） | Schild SE. Radiation therapy（RT）after prostatectomy:The case for salvage therapy as opposed to adjuvant therapy. Int J Cancer. 2001 20;96（2）:94-8. |
